The review further summarizes recent advances in stratifying MASLD into distinct clusters, examining intricate associations with cardiometabolic comorbidities, and critically evaluates novel therapeutic approaches targeting GALA modulation.<h4>Recent findings</h4>MASLD can show heterogeneous phenotypes. This evidence concerns the gene GLA and metabolic dysfunction-associated steatotic liver disease.